

## RISK FACTORS FOR DEVELOPMENT OF ACNE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH UPADACITINIB

David T. Rubin

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

**In a prospective real-world study of 119 IBD patients treated with upadacitinib, 29% developed acne within a median of 31 days, occurring only at the 45 mg/d dose and significantly associated with younger age.**

### KEY POINTS

- 35 of 119 patients (29%) reported acne as an adverse event, primarily involving the face but also scalp and back, with only 2 patients (5.7%) discontinuing treatment due to acne.
- Median time to acne onset was 31 days (IQR 18-49 days) from UPA initiation.
- All acne cases occurred in patients receiving 45 mg/d; no cases occurred in the 10 patients receiving 15 mg/d.
- Multivariate regression analysis (AUC 0.6737) showed younger age was significantly associated with acne development ( $P=0.047$ ), while female sex, IBD type, smoking status, and concomitant immunomodulator or corticosteroid use were not significantly associated.
- The study provides real-world safety data to inform patient counseling about acne risk with upadacitinib in IBD.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/05974e50-743d-11ee-b9a8-0242ac140004>



**AI-generated summary**

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.